Published in Glia on June 01, 2008
Krüppel-like factor 4, a novel transcription factor regulates microglial activation and subsequent neuroinflammation. J Neuroinflammation (2010) 1.15
The evolving landscape of neurotoxicity by unconjugated bilirubin: role of glial cells and inflammation. Front Pharmacol (2012) 0.96
Role of prostaglandins in neuroinflammatory and neurodegenerative diseases. Mediators Inflamm (2012) 0.91
Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia. J Neuroinflammation (2012) 0.90
The endotoxin-induced neuroinflammation model of Parkinson's disease. Parkinsons Dis (2011) 0.89
Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia. J Neuroinflammation (2010) 0.85
Microsomal prostaglandin E synthase-1 and cyclooxygenase-2 are both required for ischaemic excitotoxicity. Br J Pharmacol (2010) 0.84
Stressor-like effects of c-Jun N-terminal kinase (JNK) inhibition. PLoS One (2012) 0.81
Prostaglandin E2 synthases in neurologic homeostasis and disease. Prostaglandins Other Lipid Mediat (2009) 0.80
Inhibition of Neuroinflammation in LPS-Activated Microglia by Cryptolepine. Evid Based Complement Alternat Med (2013) 0.79
Poly(I:C) increases the expression of mPGES-1 and COX-2 in rat primary microglia. J Neuroinflammation (2016) 0.78
Rice bran derivatives alleviate microglia activation: possible involvement of MAPK pathway. J Neuroinflammation (2016) 0.76
Non-Steroidal Anti-Inflammatory Drugs and Brain Inflammation: Effects on Microglial Functions. Pharmaceuticals (Basel) (2010) 0.76
Downregulation of mPGES-1 Expression via EGR1 Plays an Important Role in Inhibition of Caffeine on PGE2 Synthesis of HBx(+) Hepatocytes. Mediators Inflamm (2015) 0.76
NF-kappaB induces PGE2-synthesizing enzymes in neurons. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.76
Effect of pregabalin on contextual memory deficits and inflammatory state-related protein expression in streptozotocin-induced diabetic mice. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.76
Alleviation of Microglial Activation Induced by p38 MAPK/MK2/PGE2 Axis by Capsaicin: Potential Involvement of other than TRPV1 Mechanism/s. Sci Rep (2017) 0.75
Misoprostol Reverse Hippocampal Neuron Cyclooxygenase-2 Downstream Signaling Imbalance in Aluminum-Overload Rats. Curr Alzheimer Res (2016) 0.75
Inhibition of STAT3- and MAPK-dependent PGE2 synthesis ameliorates phagocytosis of fibrillar β-amyloid peptide (1-42) via EP2 receptor in EMF-stimulated N9 microglial cells. J Neuroinflammation (2016) 0.75
Microsomal Prostaglandin E Synthase-1 Expression in Inflammatory Conditions Is Downregulated by Dexamethasone: Seminal Role of the Regulatory Phosphatase MKP-1. Front Pharmacol (2017) 0.75
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Dtsch Arztebl Int (2010) 3.67
The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. Dtsch Arztebl Int (2010) 3.36
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
What users think about the differences between caffeine and illicit/prescription stimulants for cognitive enhancement. PLoS One (2012) 2.44
Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev (2012) 2.43
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14
Neural correlates of antinociception in borderline personality disorder. Arch Gen Psychiatry (2006) 1.78
Declaration and Handling of Conflicts of Interest in Guidelines: A Study of S1 Guidelines From German Specialist Societies From 2010-2013. Dtsch Arztebl Int (2015) 1.68
Therapeutic efficacy of ozone in patients with diabetic foot. Eur J Pharmacol (2005) 1.61
An intensive treatment program of interpersonal psychotherapy plus pharmacotherapy for depressed inpatients: acute and long-term results. Am J Psychiatry (2007) 1.50
Frontolimbic brain abnormalities in patients with borderline personality disorder: a volumetric magnetic resonance imaging study. Biol Psychiatry (2003) 1.48
Self-stigma, empowerment, and perceived legitimacy of discrimination among women with mental illness. Psychiatr Serv (2006) 1.48
State affective instability in borderline personality disorder assessed by ambulatory monitoring. Psychol Med (2007) 1.45
Self-stigma in women with borderline personality disorder and women with social phobia. J Nerv Ment Dis (2006) 1.39
[Practice example: neurodegenerative disorders: randomised controlled multicentre trial of home-based occupational therapy for patients with dementia]. Z Evid Fortbild Qual Gesundhwes (2013) 1.38
Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats. J Neurochem (2006) 1.37
Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students. Pharmacotherapy (2013) 1.32
Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons. BMC Med (2013) 1.31
Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J Cereb Blood Flow Metab (2007) 1.30
Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther (2007) 1.29
Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry (2002) 1.28
Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem (2007) 1.28
Increased nocturnal interleukin-6 excretion in patients with primary insomnia: a pilot study. Brain Behav Immun (2005) 1.26
Cyclooxygenase inhibition in ischemic brain injury. Curr Pharm Des (2008) 1.23
Shame and implicit self-concept in women with borderline personality disorder. Am J Psychiatry (2007) 1.22
Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia. Glia (2005) 1.22
Effectiveness of inpatient dialectical behavioral therapy for borderline personality disorder: a controlled trial. Behav Res Ther (2004) 1.19
Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev (2010) 1.18
Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation (2007) 1.17
Gender differences in axis I and axis II comorbidity in patients with borderline personality disorder. Psychopathology (2009) 1.16
SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging. Neuroimage (2008) 1.16
New developments in the diagnosis of dementia. Dtsch Arztebl Int (2010) 1.16
Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J Neurochem (2009) 1.15
Affective dysregulation and dissociative experience in female patients with borderline personality disorder: a startle response study. J Psychiatr Res (2005) 1.15
Caffeic acid phenethyl ester inhibits T-cell activation by targeting both nuclear factor of activated T-cells and NF-kappaB transcription factors. J Pharmacol Exp Ther (2003) 1.14
Association of SORL1 gene variants with Alzheimer's disease. Brain Res (2009) 1.14
Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs (2005) 1.12
Reliability of three alternate forms of the trail making tests a and B. Arch Clin Neuropsychol (2011) 1.11
Inhibition of LPS-induced p42/44 MAP kinase activation and iNOS/NO synthesis by parthenolide in rat primary microglial cells. J Neuroimmunol (2002) 1.09
Attention-deficit hyperactivity disorder as a potentially aggravating factor in borderline personality disorder. Br J Psychiatry (2008) 1.09
Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network. Dement Geriatr Cogn Disord (2009) 1.08
Microglial activation in Alzheimer's disease. Curr Alzheimer Res (2009) 1.06
Coumarins from Opopanax chironium. New dihydrofuranocoumarins and differential induction of apoptosis by imperatorin and heraclenin. J Nat Prod (2004) 1.06
Traditionally used Thai medicinal plants: in vitro anti-inflammatory, anticancer and antioxidant activities. J Ethnopharmacol (2010) 1.06
Deep brain stimulation for treatment of refractory depression. Lancet (2005) 1.06
Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study. Eur Psychiatry (2006) 1.05
Elevated pain thresholds correlate with dissociation and aversive arousal in patients with borderline personality disorder. Psychiatry Res (2006) 1.04
Increased delta power and discrepancies in objective and subjective sleep measurements in borderline personality disorder. J Psychiatr Res (2005) 1.02
A comparison of different automated methods for the detection of white matter lesions in MRI data. Neuroimage (2011) 1.02
The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis (2012) 1.02
Measuring shame and guilt by self-report questionnaires: a validation study. Psychiatry Res (2007) 1.01
Increased apparent diffusion coefficients on MRI linked with matrix metalloproteinases and edema in white matter after bilateral carotid artery occlusion in rats. J Cereb Blood Flow Metab (2008) 1.01
Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression. Neuropharmacology (2011) 1.00
Inhibition of LPS-induced iNOS and NO synthesis in primary rat microglial cells. Neurochem Int (2003) 1.00
Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Nat Clin Pract Neurol (2007) 1.00
Posterior cortical atrophy: variant of Alzheimer's disease? A case series with PET findings. J Neurol (2005) 0.99
Regional distribution of the prostaglandin E2 receptor EP1 in the rat brain: accumulation in Purkinje cells of the cerebellum. J Mol Neurosci (2005) 0.99
Effects of the cyclooxygenase-2 inhibitor nimesulide on cerebral infarction and neurological deficits induced by permanent middle cerebral artery occlusion in the rat. J Neuroinflammation (2005) 0.99
Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. Eur Arch Psychiatry Clin Neurosci (2014) 0.98
The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.98
Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat. Brain Res (2004) 0.98
Life context of pharmacological academic performance enhancement among university students--a qualitative approach. BMC Med Ethics (2014) 0.98
Tissue inhibitor of metalloproteinases-3 mediates the death of immature oligodendrocytes via TNF-α/TACE in focal cerebral ischemia in mice. J Neuroinflammation (2011) 0.96
Cyclooxygenase-1 and -2 differentially modulate lipopolysaccharide-induced blood-brain barrier disruption through matrix metalloproteinase activity. J Cereb Blood Flow Metab (2009) 0.96
Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest (2003) 0.96
Spatiotemporal correlations between blood-brain barrier permeability and apparent diffusion coefficient in a rat model of ischemic stroke. PLoS One (2009) 0.96
Incensole acetate: a novel neuroprotective agent isolated from Boswellia carterii. J Cereb Blood Flow Metab (2008) 0.96
Arzanol, an anti-inflammatory and anti-HIV-1 phloroglucinol alpha-Pyrone from Helichrysum italicum ssp. microphyllum. J Nat Prod (2007) 0.95
Serotonin via 5-HT7 receptors activates p38 mitogen-activated protein kinase and protein kinase C epsilon resulting in interleukin-6 synthesis in human U373 MG astrocytoma cells. J Neurochem (2005) 0.94
Extraction of prefronto-amygdalar pathways by combining probability maps. Psychiatry Res (2009) 0.94
A coordinate-based ALE functional MRI meta-analysis of brain activation during verbal fluency tasks in healthy control subjects. BMC Neurosci (2014) 0.94
Psychological interventions for antisocial personality disorder. Cochrane Database Syst Rev (2010) 0.94
Neuropsychological differentiation of small vessel disease, Alzheimer's disease and mixed dementia. J Neurol Sci (2002) 0.93
Neural correlates of interference inhibition, action withholding and action cancelation in adult ADHD. Psychiatry Res (2012) 0.93
Incensole acetate, a novel anti-inflammatory compound isolated from Boswellia resin, inhibits nuclear factor-kappa B activation. Mol Pharmacol (2007) 0.93
Inferior frontal white matter microstructure and patterns of psychopathology in women with borderline personality disorder and comorbid attention-deficit hyperactivity disorder. Neuroimage (2007) 0.93
Similar protective effect of ischaemic and ozone oxidative preconditionings in liver ischaemia/reperfusion injury. Pharmacol Res (2002) 0.92
[Characteristics of university students using stimulants for cognitive enhancement: a pilot study]. Psychiatr Prax (2012) 0.92
How are memory complaints in functional memory disorder related to measures of affect, metamemory and cognition? J Psychosom Res (2009) 0.91
Calcium ionophoretic and apoptotic effects of ferutinin in the human Jurkat T-cell line. Biochem Pharmacol (2004) 0.91
Role of prostaglandins in neuroinflammatory and neurodegenerative diseases. Mediators Inflamm (2012) 0.91
Neurovascular protection by post-ischemic intravenous injections of the lipoxin A4 receptor agonist, BML-111, in a rat model of ischemic stroke. J Neurochem (2013) 0.90
Interleukin-1 beta-induced expression of the prostaglandin E-receptor subtype EP3 in U373 astrocytoma cells depends on protein kinase C and nuclear factor-kappaB. J Neurochem (2006) 0.90
The impact of posttraumatic stress disorder on dysfunctional implicit and explicit emotions among women with borderline personality disorder. J Nerv Ment Dis (2007) 0.90
Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia. J Neuroinflammation (2012) 0.90